Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeAchievedLatest Earnings (2026-05-11): "Cited as achieved"

Phase III Trial of LF111 for Contraception

First written in FY2022. 2 of 5 entries say "Advanced", first in FY2023. Latest entry: 2026-05-11.

5entries
5years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022AdvancedFY2023 – FY20252022: 120222023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
LF111 Phase 3 Trial for Contraceptive Use and ApprovalA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. 2026-05-11Cited as achievedEarnings

    「LF111 (drospirenone), which was being developed for contraception, received approval in May 2025.」

    The company cited the already completed marketing approval for LF111 as an achievement.
  2. FY2025AchievedAnnual report

    「臨床開発につきましては、避妊を適応症として開発中のLF111（ドロスピレノン）について、2025年5月19日に製造販売承認を取得いたしました。」

    LF111について、製造販売承認申請準備段階から、2025年5月19日の製造販売承認取得へ到達した。
  3. FY2024AdvancedAnnual report

    「さらに避妊を適応症として開発中のLF111（ドロスピレノン）について、2025年３月期第１四半期中の製造販売承認申請に向け準備を進めております。」

    LF111について、PhaseⅢ試験実施中から、2025年3月期第1四半期中の製造販売承認申請準備段階へ進んでいる。
  4. FY2023AdvancedAnnual report

    「避妊を適応症として開発中のLF111（ドロスピレノン）について、PhaseⅢ試験を実施中であります。」

    LF111はPhaseⅠ/Ⅱ試験終了・PhaseⅢ試験開始の段階から、PhaseⅢ試験を実施中の状態へ進んでいる。
  5. FY2022First statedAnnual report

    「LF111 (drospirenone), which is being developed for contraception, has completed its Phase I/II trials and begun a Phase III trial.」

    The development status of LF111 is described as having advanced from completion of Phase I/II trials to the start of a Phase III trial.
Moved together

"Development and Launch of a Hair Hormone Measurement Kit" moved the same way as this thread, in the same document, in 3 of its 5 moves.

333222★123456
  1. ★This thread
  2. 1Development and Launch of a Hair Hormone Measurement Kit3×
  3. 2Reviewing the Rationale for Cross-Shareholdings and Selling Them3×
  4. 3Launch of the Dysmenorrhea Treatment DroEthi3×
  5. 4Overseas Business Expansion Focused on Asia2×
  6. 5FY2025 Sales and Profitability Targets and the Vision of a Total Healthcare Company2×
  7. 6Establishment of an ESG Committee and Identification of 17 Material Issues2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Earnings of 2026-05-11: "Cited as achieved".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.